Belite Bio's lead drug, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data expected by late 2024 or early 2025. Tinlarebant works by reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback